A legitimate online pathway begins with a clinician
Online access to semaglutide should begin with a clinical assessment, a prescription when appropriate and dispensing through a verified pharmacy. A website accepting payment is not proof of eligibility, prescribing quality or lawful access. Bring your medical history, medicine list and prior treatment experience to the clinician.
Ask which legal clinical entity conducts the assessment and who will be your prescriber. Verify the clinician’s state license and the dispensing pharmacy with the relevant boards. A provider’s marketing description is not an independent license or quality check.
Sources: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA
Specify the product before comparing prices
Wegovy and Ozempic contain semaglutide, but they have different labeled uses and product instructions. Wegovy has weight-management indications and now has approved injectable and oral formulations. Ozempic is a diabetes medicine with specified additional risk-reduction indications. A shared active ingredient does not mean all products have the same indication, dose or instructions.
A compounded injection, dissolvable preparation or tablet is not automatically an approved brand or an approved generic. The name of an ingredient does not establish the effectiveness, stability or quality of a different formulation. Request the exact prescription name, dose, route and pharmacy.
Sources: Wegovy prescribing information · Ozempic prescribing information
Compare care and medication as separate charges
Membership, visits, medication, laboratory testing, supplies and shipping can be separate payments. Some offers bundle them, others do not. Compare the total initial payment, anticipated renewal and plan commitment rather than a headline starting price.
Ro, for example, lists a first-month care fee followed by a higher monthly renewal or a lower annual prepaid equivalent, with medication separate. A manufacturer-linked pharmacy offer can have its own dose restrictions and expiry date. Lower-cost entry medication is not necessarily the maintenance-dose price.
If you use insurance, ask the plan or pharmacy to confirm the prescription’s coverage, prior-authorization conditions and copay after any deductible. A provider offering coverage support does not guarantee approval. If you pay cash, ask whether you can continue under the same terms after the promotion ends.
Sources: Weight Loss Program Pricing | Ro · Weight Loss - Ro Body Membership | Ro · Get Your GLP-1 Medications Delivered with NovoCare® Pharmacy | NovoCare®
Compounded access has separate limitations
FDA’s current guidance says compounded medicine is not reviewed for safety, effectiveness or quality before marketing. Its April 2026 update says semaglutide and tirzepatide are not on the drug shortage list or the 503B bulks list. An old shortage explanation does not establish the current basis for a prescription.
Ask why an approved product cannot meet the medical need, what specific preparation is proposed and which pharmacy makes it. A vitamin additive or a “personalized” label does not independently establish compliance or clinical effectiveness. Avoid no-prescription offers and products sold as research chemicals.
Sources: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA · FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA
Plan for refills and treatment changes
Find out who approves dose changes, how refills are requested, when payment becomes non-refundable and how to report an adverse effect. Ask how the provider handles a missed shipment, a warm injectable package or a drug shortage affecting your prescription. Do not improvise an alternative formulation.
A subscription cancellation can end clinical access as well as medication shipments. Arrange any transfer or follow-up before changing providers. Keep the prescription, written quote, fulfillment policy and cancellation confirmation together so that medical and financial decisions remain clear.
No directory can identify the best provider for every patient. These comparisons describe public documents, not tested clinical performance. Use the evidence and unresolved questions to choose a clinician-supported route that fits your history and budget.
Sources: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA · Wegovy prescribing information · Ozempic prescribing information